Erik Gatenholm

We'd done some very, very fantastic tests, had awesome results, and we were ready to go into actual clinical.

Did it have revenue or no?

We were pre-revenue.

We were pre-revenue.

I can't go into numbers, unfortunately.

We're still under a good NDA until, I think, 2018.

But it was fair.

It was completely fair.

And the point was really to keep me motivated to come back and do this master.

And I felt it was my time.

I could not contribute any more to the business because the business was going through more towards the clinical stages as a biotech company has to go through.

Um, and I really felt like, you know, I can't contribute more to the company.

Well, it's, you know, it's interesting.

Again, so my mentors were telling me, you know, you're in a very special field.

You're very young and you're in a field where a lot of people have their PhDs completed.

How old are you today, Eric?

26.

So they've been in the field for 10, 20 years.

They have this massive industrial experience.

They've built up this experience based on their PhDs and their MBAs, etc.